n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases

The n-Lorem Foundation and the EspeRare Foundation announced today a strategic collaboration to expand access in Europe to ...
Morningstar

n-Lorem Foundation Organizes Third Annual Nano-rare Patient Colloquium, Highlighting Scientific and Clinical Advancements Achieved Since Organization’s Founding

n-Lorem, a nonprofit foundation, announced today that it will hold its third annual Nano-rare Patient Colloquium in Cambridge, Mass., where n-Lorem leaders and experts in the field will share updates ...
Business Wire

GondolaBio and n-Lorem Foundation Partner to Advance Novel ASO Therapies for Genetic Diseases

PALO ALTO, Calif. & SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for ...
MarketWatch

n-Lorem Foundation Identifies New, Important Roles of JIP3, Offering Critical Insights into Therapeutic Approaches for Nano-rare Patients

-- Research, supported by the Wolverine Foundation and published in JCI Insights, characterizes a mutation in MAPK8IP3 that disrupts dopamine signaling SAN DIEGO--(BUSINESS WIRE)--May 08, 2025-- ...
Precision Medicine Online

N-Lorem Foundation, EspeRare Partner to Expand Access to ASO Therapies in Europe

The partners will focus on treating Swiss patients with very rare diseases and then use the framework developed to establish similar pathways throughout Europe.